Completed PHASE1 INTERVENTIONAL 2-arm NCT03426033

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

Phase 1, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Sponsor: Akcea Therapeutics

Conditions Cardiovascular Diseases Elevated Lipoprotein(a)

Interventions ISIS 681257 Warfarin

Updated 6 times since 2018 Last updated: Apr 3, 2018 Started: Dec 15, 2017 Primary completion: Feb 25, 2018 Completion: Feb 25, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cardiovascular Diseases and Elevated Lipoprotein(a) and is currently completed. Akcea Therapeutics leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Mar 2018 — May 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akcea Therapeutics

Data source: Akcea Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mount Royal, Canada